Koiwa, Fumihiko
Sato, Yu
Ohara, Meiko
Nakanishi, Kaoru
Fukagawa, Masafumi
Akizawa, Tadao
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
https://doi.org/10.1038/s41598-023-45080-9
Article History
Received: 5 April 2023
Accepted: 16 October 2023
First Online: 4 November 2023
Competing interests
: F.K. received consulting fees and honoraria from, and served on an Advisory Board for, Kyowa Kirin Co., Ltd. Y.S. and M.O. are employees of Kyowa Kirin Co., Ltd. K.N. is an employee of and holds stock or stock options in Kyowa Kirin Co., Ltd. M.F. received grants from Kyowa Kirin Co., Ltd. to his institution; consulting fees from Sanwa Kagaku Kenkyusho Co., Ltd. and Ono Pharmaceutical Co., Ltd.; and honoraria from Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd., and Kissei Pharmaceutical Co., Ltd. T.A. received consulting fees and honoraria from Kyowa Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin, Ltd., and Sanwa Kagaku Kenkyusho Co., Ltd.